Safoni, ImmuNext to Team Up to Develop INX-021 Antibody for Autoimmune Disorders
Sanofi will work with ImmuNext to develop INX-021, a CD40L monoclonal antibody designed to suppress overactive cell signals associated with autoimmune disorders, including lupus and multiple sclerosis. Under the agreement, Sanofi will have an exclusive license to further develop and commercialize INX-021, a synthetic antibody from ImmuNext that is now in preclinical…